Schmallenberg virus (SBV) vaccine, methods of production, and uses thereof
AssigneeBoehringer Ingelheim Vetmedica GmbH
InventorsVeljko Nikolin, Konrad Stadler, Axel Lischewski, Alexander Brix, Jeffrey P. Knittel, Katharina Hedwig Toepfer
Life of this patent
Estimating the term…
Abstract
The present invention relates to the field of vaccines and medicaments for the prophylaxis and treatment of infectious diseases in ruminants. In particular, it relates to inactivated Schmallenberg virus (SBV) useful as vaccine or medicament for preventing or treating viremia, the transmission and clinical symptoms, in particular malformations in newborn ruminants such as cattle, sheep and goats, induced by SBV.
Claims8
A method of generating an immune response to SBV in an animal comprising administering to said animal an immunogenic composition comprising:
- a. an aziridine compound-inactivated Schmallenberg virus (SBV) in an amount which is equivalent to a virus titer of at least about 104 TCID50/mL per dose, wherein the inactivated SBV comprises a medium (M) RNA segment having a sequence that is inverse complementary to a nucleic acid sequence having at least 95% sequence identity with the nucleic acid sequence of SEQ ID NO:2 over the whole length of SEQ ID NO:2;
- and
- b. the aziridine compound binary ethyleneimine (BEI) neutralized with sodium thiosulphate wherein the immunogenic composition further comprises aluminum hydroxide and saponin.
A method of inducing an immune response against SBV in a herd of animals comprising comprising the step of administering an immunogenic composition comprising:
- a. an aziridine compound-inactivated Schmallenberg virus (SBV) in an amount which is equivalent to a virus titer of at least about 104 TCIDso/mL per dose, wherein the inactivated SBV comprises a medium (M) RNA segment having a sequence that is inverse complementary to a nucleic acid sequence having at least 95% sequence identity with the nucleic acid sequence of SEQ ID NO:2 over the whole length of SEQ ID NO:2;
- and
- b. the aziridine compound binary ethyleneimine (BEI) neutralized with sodium thiosulphate, wherein the immunogenic composition further comprises aluminum hydroxide and saponin.
Dependencies are inferred from the claim text.